Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial. (26th December 2018)

• Record Type: Journal Article
• Authors: Montero‐Odasso, M.; Speechley, M.; Chertkow, H.; Sarquis‐Adamson, Y.; Wells, J.; Borrie, M.; Vanderhaeghe, L.; Zou, G. Y.; Fraser, S.; Bherer, L.; Muir‐Hunter, S. W.
• Is Part Of: European journal of neurology. Volume 26:Number 4(2019)
• Page Start: 651
• Page End: 659
• Publication Date: 2018-12-26
• Subjects: gait disorders -- cognitive disorders and dementia -- donepezil -- falls -- mild cognitive impairment -- neurological disorders -- randomized controlled trial; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.13872
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: Cognitive enhancers are commonly prescribed to people with Alzheimer's disease and related dementias to improve cognition and function. However, their effectiveness for individuals in the pre‐stages of dementia, particularly in functional motor outcomes, remains unknown. We aimed to determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic neurotransmission, on gait performance in mild cognitive impairment (MCI). Methods: This was a double‐blind, placebo‐controlled trial including 60 older adults with MCI, randomized to receive donepezil (10 mg/daily, maximal dose) or placebo. Primary outcome was gait speed (cm/s) under single and three dual‐task conditions (counting backwards by 1 or 7 and naming animals) measured using an electronic walkway. Dual‐task gait cost (DTC), a valid measure of motor–cognitive interaction, was calculated as the percentage change between single ( S ) and dual‐task ( D ) gait speeds: [( S − D )/ S ] × 100. Secondary outcomes included attention, executive function, balance and falls. Results: After 6 months, the donepezil group experienced an improvement in dual‐task gait speed (range 4–11 cm/s), although this was not statistically significant. The donepezil group showed a significant reduction in DTC (improvement) by counting backwards by 1 and 7 compared with placebo (10.25% vs. 1.75%, P = 0.048; 21.38% vs. 14.64%, P = 0.037, intention‐to‐treat analysis). Per‐protocol analyses showed that all three DTCs improved in the donepezil group, along with a non‐significant reduction of rate of falls. Conclusions: Donepezil treatment improved dual‐task gait speed and DTC in elderly patients with MCI. Our results support the concept of reducing falls in MCI by targeting the motor–cognitive interface.